Growth & profitability
- Revenue has grown 16.9% per year over the past 5 years.
- Operating margin has expanded, at 12.6% in the latest year.
NAGE Financials Niagen Bioscience, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $129M | $17M | 64.3% | 12.6% | — | — | $65M |
| 2024 | $100M | $9M | 61.8% | 7.8% | — | — | $45M |
| 2023 | $84M | -$5M | 60.8% | -6.7% | — | — | $27M |
| 2022 | $72M | -$17M | 59.4% | -25.9% | — | — | $20M |
| 2021 | $67M | -$27M | 61.5% | -40.1% | — | — | $28M |
| 2020 | $59M | -$20M | 59.5% | -33.5% | — | — | $17M |
| 2019 | $46M | -$32M | 55.7% | -67.6% | -$21M | — | $19M |
| 2018 | $32M | -$33M | 50.9% | -105.1% | -$22M | — | $23M |
| 2017 | $21M | -$11M | 49.4% | -77.2% | -$11M | — | — |
| 2016 | — | -$3M | — | — | -$4M | $0 | — |
| 2016 | — | -$3M | — | — | -$3M | $5M | — |
| 2015 | — | -$5M | — | — | -$3M | $3M | — |
| 2013 | — | -$4M | — | — | -$4M | — | — |
| 2012 | — | -$12M | — | — | -$10M | — | — |
| 2011 | — | -$8M | — | — | -$4M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $31M | $6M | 63.5% | 5.0% | — | — | $67M |
| Dec '25 | $34M | $4M | 64.1% | 12.1% | — | — | $65M |
| Sep '25 | $34M | $5M | 64.5% | 12.5% | — | — | $64M |
| Jun '25 | $31M | $4M | 65.0% | 10.2% | — | — | $60M |
| Mar '25 | $30M | $5M | 63.4% | 15.7% | — | — | $56M |
| Dec '24 | $29M | $7M | 62.5% | 24.4% | — | — | $45M |
| Sep '24 | $26M | $2M | 63.5% | 6.3% | — | — | $32M |
| Jun '24 | $23M | -$15000 | 60.2% | -1.1% | — | — | $28M |
| Mar '24 | $22M | -$492000 | 60.7% | -3.3% | — | — | $28M |
| Dec '23 | $21M | $114000 | 61.0% | -0.8% | — | — | $27M |
| Sep '23 | $19M | -$959000 | 61.4% | -5.9% | — | — | $27M |
| Jun '23 | $20M | -$2M | 60.8% | -11.4% | — | — | $26M |
| Mar '23 | $23M | -$2M | 59.9% | -8.7% | — | — | $23M |
| Dec '22 | $21M | -$1M | 57.2% | -6.9% | — | — | $20M |
| Sep '22 | $17M | -$985000 | 59.8% | -18.0% | — | — | $13M |
| Jun '22 | $17M | -$6M | 60.0% | -38.2% | — | — | $17M |
| Mar '22 | $17M | -$8M | 61.0% | -44.8% | — | — | $21M |
| Dec '21 | $18M | -$5M | 61.2% | -29.9% | — | — | $28M |
| Sep '21 | $17M | -$9M | 61.1% | -51.1% | — | — | $33M |
| Jun '21 | $18M | -$6M | 61.1% | -31.4% | — | — | $39M |
Valuation over time
How the market has priced NAGE against its own fundamentals since 2025-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 64.2× (Mar '25) to 15.1× (Jun '26).
- The price-to-sales ratio has fallen from 5.5× (Mar '25) to 2.0× (Jun '26).
P/E
P/S
Frequently asked questions
Is NAGE growing its revenue and profit?
Over the past 5 years, Niagen Bioscience, Inc.'s revenue has grown 16.9% per year. These are computed facts, not advice.
How much debt does NAGE have?
As of FY2025, Niagen Bioscience, Inc. reported — of total debt against $65M of cash.
What is NAGE's profit margin?
In FY2025, gross margin was 64.3%, operating margin 12.6%, and net margin 13.4%.
What is NAGE's P/E ratio?
As of Jun '26, Niagen Bioscience, Inc. traded at a price-to-earnings ratio of about 15.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.